What it's for (Indications)
- Strontium ranelate (e.
- g.
- , Rontilate) is primarily indicated for the treatment of severe osteoporosis in postmenopausal women and adult men who are at a high risk of fracture.
- This treatment is specifically reserved for patients for whom other medicinal products approved for osteoporosis are considered unsuitable due to documented intolerability, contraindications, or an inadequate response to prior therapies.
- The clinical decision to initiate strontium ranelate must be made after a comprehensive evaluation of the patient's individual cardiovascular risk profile, carefully weighing the potential benefits against the serious cardiovascular and thrombotic risks associated with its use.
- Its role is to reduce the risk of vertebral and non-vertebral fractures in this specific patient population.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of strontium ranelate is 2 grams once daily. This dose should be taken orally as an sachet, which is to be dissolved in a glass of water and consumed immediately. For optimal absorption and to minimize potential interactions, it is crucial that strontium ranelate be taken preferably at bedtime, and strictly at least two hours after food, milk, or calcium-containing products. Furthermore, it must be administered at least two hours before taking antacids, iron supplements, or magnesium supplements. Consistent daily adherence to this dosing schedule and separation from other ingestibles is paramount for maximizing therapeutic efficacy and safety. Patients should also maintain adequate calcium and vitamin D intake, typically through diet or supplementation, as part of their overall osteoporosis management plan. Regular monitoring of renal function is recommended throughout the treatment period. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with strontium ranelate include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, which typically occur at the beginning of treatment.
- Other frequently observed adverse reactions may involve headache, dermatitis, eczema, and transient cognitive disorders, including memory impairment.
- More serious, though less frequent, adverse events necessitate immediate medical attention.
- These include a significantly increased risk of venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, as well as an elevated risk of myocardial infarction and other serious cardiovascular events.
- Hypersensitivity reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, which can be life-threatening, have also been reported.
- Patients should be advised to promptly report any unusual symptoms, skin rashes, or worsening medical conditions to their healthcare provider for evaluation.
Serious Warnings
- Black Box Warning: **Serious Warnings: Cardiovascular and Thrombotic Risks** Strontium ranelate is associated with a significantly increased risk of serious cardiovascular events, including myocardial infarction (heart attack), and an elevated risk of venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism. These severe risks necessitate careful patient selection and ongoing monitoring. Due to these concerns, strontium ranelate is explicitly contraindicated in patients with established ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. It is also contraindicated in individuals with uncontrolled hypertension, a history of venous thromboembolism, or in patients who are temporarily or permanently immobilized. Before initiating treatment, healthcare professionals must conduct a comprehensive assessment of the patient's cardiovascular risk factors and ensure these contraindications are not present. During treatment, patients should be closely monitored for any new onset or worsening cardiovascular symptoms (e.g., chest pain, shortness of breath, sudden leg swelling or pain) or neurological events (e.g., sudden weakness, vision disturbances, speech difficulty) and advised to seek immediate medical attention if such symptoms occur. The use of strontium ranelate should be restricted to patients for whom other approved osteoporosis treatments are unsuitable due to the substantial nature of these cardiovascular and thrombotic hazards.
- Strontium ranelate carries substantial safety warnings, particularly concerning cardiovascular and thrombotic risks.
- Prior to initiating treatment and periodically thereafter, a thorough cardiovascular risk assessment must be performed, as the drug is associated with an increased risk of myocardial infarction and venous thromboembolism (VTE).
- Special caution is advised in patients with a history of hypertension, and blood pressure should be regularly monitored and effectively controlled.
- Serious cutaneous adverse reactions, including DRESS syndrome, which can be fatal, have been reported; patients should be counselled to immediately report any new skin rash, fever, or lymphadenopathy.
- Renal function must be regularly monitored, and treatment should be discontinued if creatinine clearance falls below 30 mL/min, as it is contraindicated in severe renal impairment.
- Healthcare professionals must carefully weigh the clinical benefits against these serious risks on an individualized patient basis, restricting its use to those for whom alternative osteoporosis treatments are unsuitable.
How it Works (Mechanism of Action)
Strontium ranelate exerts its therapeutic effects on bone metabolism through a unique dual mechanism of action, concurrently promoting bone formation and inhibiting bone resorption. The strontium ion, a divalent cation, is believed to mimic calcium in some biological processes within bone tissue. It stimulates the proliferation and differentiation of pre-osteoblastic cells, thereby enhancing bone matrix synthesis by mature osteoblasts. Simultaneously, it reduces the differentiation and activity of osteoclasts, leading to a decrease in bone resorption. This dual action helps to rebalance the bone remodeling process, which is often disrupted in osteoporosis. The net effect is an increase in bone mineral density (BMD), an improvement in bone microarchitecture, and a subsequent reduction in the risk of both vertebral and non-vertebral fractures. The ranelate moiety is generally considered pharmacologically inactive, primarily serving as a stable carrier for the strontium ion.